Speaker Profile

Research Advocate/Patient Advocate, UCSF Breast Science Advocacy Core

Over 30 years of experience in life science consulting, investment and portfolio management, advising biotech, pharma, diagnostics and device companies, investment firms, universities and government agencies worldwide. Co-founder, venture partner and key person of Global Biomedical Partners, managing International Biomedicine Holdings, a $400 million fund based in Basel, Switzerland. Former member of Board of Directors of Innodia, Inc. and Board observer of Syntonix Pharmaceuticals. Business analyst in the corporate venture capital office of WR Grace & Co. A breast cancer survivor since 2000, Vivian applies her personal experience as a patient and professional experience as a life science industry consultant to her cancer advocacy work. Vivian collaborates with research investigators at academic institutions across the US and abroad to provide patient perspective in shaping grant applications to, and research projects funded by, US Department of Defense (DoD), California Breast Cancer Research Program (CBCRP), Susan G. Komen, Sidney Kimmel Foundation, American Society of Clinical Oncology (ASCO)’s Conquer Cancer Foundation and Patient-Centered Outcomes Research Institute (PCORI). She is an Advocate Advisor to the University of California’s Athena Breast Health Network, providing patient input for its WISDOM Study on personalized breast cancer screening, for which Athena has been awarded a $14 million Pragmatic Clinical Studies grant by PCORI. Vivian has served as a Consumer Reviewer for the DoD Breast Cancer Research Program, and as a Peer Reviewer for Komen grants on the national and local levels. She has served as an Advocate Observer on the California Breast Cancer Research Program (CBCRP) Community Impact Review Panel. Vivian serves on the Volunteer Leadership Council of the American Cancer Society’s California Chinese Unit and is a member of Bay Area Young Survivors (BAYS), mentoring newly diagnosed patients. Vivian is a member of Komen’s Advocate In Sciences program and a graduate of National Breast Cancer Coalition’s Project LEAD Institute as well as Research Advocacy Network’s Focus on Science scholar program. She earned her Bachelor’s degree in Biochemistry from Harvard University and conducted research in the Tumor Immunology department of Dana Farber Cancer Center.

 Session Abstract – PMWC 2022 Silicon Valley

Track 3, June 28

The diagnosis, risk stratification, and treatment of cancer have become increasingly personalized. Clinicians utilize novel testing technologies to select targeted therapeutics based on predictive biomarkers. The advent of newer and less invasive approaches to diagnosis such as liquid biopsy is enabling clinicians to better tailor treatment plans for their patients. Novel immunotherapy agents used alone or in combination with other agents may further optimize outcomes for patients with advanced disease. This session will explore the unique challenges that community-based clinicians face in their practice.